Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Add like
Add dislike
Add to saved papers

The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.

Animal models of proliferative vitreoretinopathy in which the intact vitreous body is injected with large numbers of fibroblasts do not resemble the human situation. Using a refined rabbit model of proliferative vitreoretinopathy in which the vitreous is compressed and partially detached from the retinal surface and small amounts of tissue-cultured homologous fibroblasts (25,000) are scattered over the vascularized part of the retina, we reevaluated the effect of intravitreally injected triamcinolone acetonide. We found that 2 mg of the corticosteroid reduced the incidence of retinal detachments from 90% to 56%. The effect was less than in previous models with intact vitreous. Large doses of the corticosteroid had no additional effect on the reduction of retinal detachments, indicating an optimal dosage of 2 mg. The effect of the corticosteroid on neovascularization was considerable; with 8 mg it could almost be prevented (reduction from 74% to 8%).

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app